

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Prolonged-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During scoping workshop discussion, it was noted that black minority groups are less likely to seek and adhere to medical advice for DRTA.

Furthermore, some people with secondary DRTA will have other conditions and may have disabilities; they therefore may have an increased risk of fractures.

It was also noted that a licensed treatment for DRTA would improve access to treatment and limit any potential equality issues associated with access to currently used off-licence preparations.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential

equality issues?
No, no changes are needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 10 May 2021